Adam Levy
About Adam Levy
Adam Levy, Ph.D., M.B.A., is Acrivon Therapeutics’ Chief Financial Officer and Principal Financial Officer effective April 1, 2025; he is 60 years old as of the 2025 proxy date . He holds an MBA in Finance from Northwestern’s Kellogg School, a PhD in Molecular Biology from the University of Illinois at Chicago, and a BS in Genetics from the University of Illinois at Urbana-Champaign . Prior to Acrivon, he led investor relations and corporate strategy roles at Zentalis Pharmaceuticals (SVP IR, 2022–2023), Turning Point Therapeutics (SVP IR & Corporate Communications, 2021–2022; acquired by BMS for $4.1B during his tenure), Alaunos Therapeutics (EVP Corporate Development & IR, 2020–2021), and Gilead Sciences (Executive Director and Head, Corporate Strategy & IR, 2016–2020); earlier roles included corporate strategy and corporate development at Pfizer, Novartis and Alexion (Head of Corporate Strategy) and an engagement manager role at McKinsey’s pharma practice . No TSR, revenue growth or EBITDA growth disclosures are provided specifically for his tenure.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Zentalis Pharmaceuticals | SVP, Investor Relations | 2022–2023 | Led IR at a clinical-stage biopharma |
| Turning Point Therapeutics | SVP, Investor Relations & Corporate Communications | 2021–2022 | Company acquired by Bristol Myers Squibb for $4.1B during his tenure |
| Alaunos Therapeutics | EVP, Corporate Development & Investor Relations | 2020–2021 | Corporate development and IR leadership |
| Gilead Sciences | Executive Director & Head, Corporate Strategy & Investor Relations | 2016–2020 | Reported directly to the CFO; led corporate strategy & IR |
| Alexion Pharmaceuticals | Head of Corporate Strategy (earlier career) | N/D | Corporate strategy leadership |
| Pfizer; Novartis | Corporate Strategy/Corporate Development (earlier career) | N/D | Roles of increasing responsibility |
| McKinsey & Company | Engagement Manager, Pharma Practice (earlier career) | N/D | Strategy consulting in pharma |
External Roles
| Role | Organization | Years | Notes |
|---|---|---|---|
| None disclosed | — | — | No public company board roles disclosed in ACRV’s proxy and 8-K biographies |
Fixed Compensation
| Component | Terms (USD) | Effective Date | Notes |
|---|---|---|---|
| Base Salary | $490,000 | Apr 1, 2025 | Per amended offer letter |
| Target Annual Bonus | 40% of base salary | Apr 1, 2025 | Pro-rated for 2025 based on promotion date |
| Relocation Reimbursement | Up to $50,000 | 9 months from Mar 14, 2025 | Must relocate near Watertown HQ; repayment of reimbursed expenses if departure within 24 months |
| Employment Status | At-will | Mar 14, 2025 | Employment may be terminated at any time by either party |
Performance Compensation
Annual Bonus Program
| Metric | Weighting | Target | Actual | Payout Form | Notes |
|---|---|---|---|---|---|
| Annual Performance Bonus | N/D | 40% of base salary | N/D | Cash/equity (company program) | Bonus eligibility per amended offer letter; NEO program determined by corporate and individual objectives |
Equity Awards – Options
| Grant Type | Grant Date | Number of Options | Exercise Price | Vesting Schedule | Notes |
|---|---|---|---|---|---|
| Stock Options | Apr 1, 2025 | 35,209 | Fair market value on grant date | 4-year vest: 25% on 1-year anniversary; then 2.083% monthly thereafter | Subject to continued service; commensurate with CFO level |
The proxy describes standard vesting mechanics for NEOs and directors (monthly or quarterly installments, with full acceleration upon change-in-control for non-employee directors; NEO acceleration terms are detailed for other executives, but Adam Levy’s change-in-control terms are not disclosed in the excerpts provided) .
Equity Ownership & Alignment
- Beneficial ownership: Adam Levy is not individually enumerated in the 2025 proxy’s beneficial ownership table as of April 21, 2025, which lists 5% holders and certain directors/executives; individual share count for Levy is not disclosed in that table .
- CFO equity alignment: Four-year option vesting creates multi-year retention and pay-for-performance linkage via share price appreciation .
Employment Terms
| Term | Detail | Source |
|---|---|---|
| Role and Effective Date | Appointed CFO and Principal Financial Officer effective Apr 1, 2025 | |
| Amended Offer Letter | Issued Mar 14, 2025; sets compensation terms and includes a Non-Disclosure, Non-Competition, Non-Solicitation & IP Agreement | |
| At-Will Employment | Employment remains at-will; can be terminated by either party at any time | |
| Relocation | Intent to relocate near Watertown HQ within ~9 months; reimbursement up to $50,000 with documentation; repay if departure within 24 months | |
| Severance/Change-in-Control | Specific CFO severance and CIC terms not disclosed in the provided filings; other NEO terms are described in the proxy |
Performance & Track Record
| Highlight | Context | Date/Period |
|---|---|---|
| Turning Point Therapeutics acquisition by BMS | $4.1B acquisition occurred during his tenure leading IR & Corporate Communications | 2021–2022 |
| Investor relations leadership at multiple biopharmas | Zentalis (SVP IR), Alaunos (EVP Corp Dev & IR), Gilead (Head Corporate Strategy & IR) | 2016–2023 |
| Investor/Media Contact at ACRV | Listed as company investor and media contact on multiple 8-K press releases | 2025 |
Investment Implications
- Alignment: The CFO’s compensation emphasizes at-risk equity via options with a four-year vesting schedule, aligning incentives with multi-year value creation and share price performance; the annual bonus is tied to corporate and individual objectives per company program .
- Retention: Relocation reimbursement with a 24-month clawback on reimbursed expenses and multi-year vesting reduce near-term departure risk; employment is at-will, and specific CFO severance/CIC economics were not disclosed in the provided materials, warranting monitoring of future filings for severance details .
- Trading signals to watch: Form 4 insider activity and any 10b5-1 plans for Levy (not included in the filings provided here); upcoming clinical and regulatory milestones that may influence bonus outcomes and equity value—Acrivon guided to updates on ACR-368 registrational-intent trial and initial ACR-2316 Phase 1 data in 2H 2025 .